Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
PITDC: Novel compound for treatment of treatment of bacterial infections and/or renal cancer disease
Active ingredient for the treatment of bacterial infections and/or renal cancer diseases More
In addition to anti-tumor activity, these compounds have been shown to be potent irreversible inhibitors of P-glycoprotein, a member of the ABC transporter protein family that has a major role in conferring multi-drug resistance. More
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
This T-cell receptor recognizes a number of human kidney tumors and is not limited to use in patients with specific MHC types. More
Surgical Instrument for Tissue Resection and Ureteral Dissection More
Peptides and antigen epitopes specific for RCC for use in the diagnosis, vaccination, or adoptive infusion of antigen specific T cells to treat patients with metastatic RCC More
Cloning and characterization of the first folliculin interacting protein FNIP-1 and purified antibodies that selectively bind to an epitope of FNIP-1 More
This invention discloses peptides for use in immunotherapy of tumors. More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Renal cell carcinoma
- Transitional cell cancer of the renal pe
- Wilms Tumour
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us